Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cambridge Heart

This article was originally published in The Gray Sheet

Executive Summary

Equity capital of $5.1 mil is raised via private placement, "primarily with a group of institutional investors," the firm reports. The financing included about 1.45 mil. unregistered common shares and 291,428 warrants. The Bedford, Massachusetts company will use a portion of the proceeds to further promote clinical adoption of its CH 2000 T-wave alternans test, cleared by FDA via 510(k) in April as the first non-invasive test to identify patients at risk of arrhythmia (1"The Gray Sheet" April 19, p. 11). Funds are also earmarked for additional clinical studies, pursuit of third-party reimbursement and "other operational needs"

You may also be interested in...

Cambridge Heart's CH 2000 Cleared To Include SCA Prognostic Indication

Cambridge Heart, Inc., expects its proprietary high-resolution electrode leads to generate additional revenue following FDA clearance of the CH 2000 T-wave alternans stress test 510(k) April 13 for the prognosis of sudden cardiac arrest.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts